Argo Biopharmaceuticals
- Biotech or pharma, therapeutic R&D
Argo Biopharma is a clinical stage biotech company that committed to developing a new generation of siRNA drugs to provide better treatments for global patients.
Argo biopharma has built a rich and differentiated pipeline of siRNA drug candidates for a wide range of indications, utilizing its industry-leading siRNA platform technology known as RADS (RNA molecules with superior Activity, Durability, and Safety).
Argo has 5 clinical programs currently in clinical trials. In early 2024, Argo announced multi-target collaboration with Novartis.